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ABSTRACT 
This study was prompted by the inconsistent reports and apparent controversies that exist 
in the biomedical literature on the responses of diabetic bladder strips to cholinergic 
nerve stimulation or exogenous administration of muscarinic agonists, especially 
acetylcholine (ACh), in vitro. In the present study, acetylcholine-induced contractions of 
urinary bladders isolated from normoglycaemic (normal) and streptozotocin-treated, 
diabetic Wistar rats were examined under physiological conditions. Mechanical 
contractile changes of the isolated urinary bladders of STZ-treated, diabetic rats in 
response to bath-applied acetylcholine were compared with those obtained from isolated 
urinary bladders of normal, age-matched, control rats. Results obtained show that urinary 
bladders from diabetic rats consistently weighed more, and were always more 
spontaneously active after mounting, than those of the age-matched normal, control rats. 
ft A 
Acetylcholine (ACh, 10" -10" M) provoked concentration-related, atropine-sensitive 
contractions of the isolated urinary bladders of both diabetic and age-matched normal, 
control rats. However, acetylcholine always induced more powerful and greater 
contractions of the diabetic bladders compared with bladders from the age-matched 
normal, control rats. The enhanced contractile responses of the diabetic bladder strips to 
bath-applied ACh were detected soon after induction of diabetes, and the magnitude 
and/or intensity of the enhanced contractile responses to ACh continued to increase as the 
diabetic state of the animals progressed. Although this preliminary study could not 
establish the mechanism of the increased contractile responsiveness of the diabetic 
xi 
bladders to the muscarinic agonist (ACh) used, the results tend to suggest that alterations 
in diabetic urinary bladder synaptosomal, vesicle-bound neurotransmitter (ACh) 
concentrations and the compensatory increase in the density of muscarinic M3-receptor 
population in diabetic bladders are two of the most attractive plausible mechanisms of the 
increased diabetic bladder responsiveness to bath-applied acetylcholine 
xn 
CHAPTER ONE 
BACKGROUND INFORMATION AND LITERATURE REVIEW 
Anatomy and Physiology of the Urinary Bladder 
Studies on the anatomy and physiology of urinary bladder are important because they 
help to understand how diseases that involve this organ occur (pathophysiology), how 
treatments and attempts to discover new drugs directed at these diseases are conducted 
(physiopharmacology). Urinary incontinence is one of the conditions that disturb diabetic 
patients, especially when diabetes has not been well controlled for a long period. 
Investigations on this condition require knowledge of histology and cytology of the 
urinary bladder in order to detect alterations caused by the disease. By knowing how 
urinary bladder contraction and relaxation are initiated, and the neurotransmitters 
involved, one may be able to see the difference that exists between a normal and a 
diseased urinary bladder. 
Anatomy of the urinary bladder 
The urinary bladder is a hollow organ that serves as a temporary reservoir of urine. 
It is located in the anterior part of the pelvis. Its position, shape and size depend on the 
amount of urine that it contains. When it is full of urine, the urinary bladder expands into 
abdominal cavity, and may reach the umbilicus. When the bladder is empty, it is enclosed 
within the pelvis, and as it fills with urine, it changes from tetrahedral to ovoid shape, and 
it can contain up to 0.5 L of urine. The bladder has an apex, a base or fundus, and a neck 
(Kolta etal, 1985). 
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The apex 
The apex is the portion of the bladder directed forwards, and it is connected by ligaments 
to the umbilical cord. 
The base 
The structure of the base depends of the sex of the individual. In the female, it is related 
to the upper wall of vagina, while in the male, the base is separated from the rectum by 
seminal vesicles and the recto-vesical pouch. 
The neck 
The neck is the lowest part of the bladder. It is located behind the pubic symphysis, and it 
is perforated by urethral orifice. In the male, urethral tube passes through the prostate. In 
the female, it forms pelvic fascia that exists on the urethra. The bladder wall is made of 
detrusor muscle that is composed of smooth muscle fibers. In the male bladder, there is 
an involuntary internal urethral sphincter towards the neck, and this sphincter contracts 
when there is ejaculation in order to prevent reflux of semen into the bladder. The 
ureteric orifices are encircled by a ring-like detrusor muscle that stops the reflux of urine 
to the bladder's ureters. The bladder interior is lined in greater part, by the mucous 
membrane attached to a muscular coat. The same muscle is folded when the bladder is 
empty. Orifices of the ureters are situated at the postero-lateral angles of the trigonum 
vesicae, while internal urethral orifice is connected to the apex of trigonum vesicae. The 
muscle of the bladder's neck is called internal sphincter. By its natural contraction, it 
prevents the emptying of the bladder before the required pressure inside the bladder is 
attained. Urethra crosses a urogenital diaphragm made by a layer of muscles, united 
together to form an external sphincter of the bladder. The external sphincter is made of 
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skeletal muscle which is under voluntary control, and it is used to prevent uncontrolled 
urination. 
The structure of urinary bladder 
The urinary bladder is composed of four layers: 
(a) Serous coat (tunica serosa); derived from the peritoneum. It covers the superior and 
the upper parts of lateral surfaces. 
(b) Muscular coat (tunica muscularis) made up of 3 layers: external, middle and internal 
layers named detrusor urinary muscle. This is a thick smooth muscle, deep layer that 
forms the internal wall of urinary bladder. 
(c) Submucous coat (tela submucosa); a layer made of areolar tissue, which joins 
together the muscular and mucous coat. 
(d) Mucus coat (tunica mucosa); thin and smooth. It is also found in ureters, in the lining 
membrane of the renal tubules and in urethra. This thin layer is also called urothelium. 
Urothelium being an epithelial lining of the urinary tract, its role was initially seen as a 
simple barrier between the urinary tract and the urine. Today, it is known that urothelium 
plays an important role in the regulation of bladder's activity, and it is involved in 
causing bladder dysfunction. The urothelium of urinary bladder is made of 3 distinct 
layers: the basal, intermediate and the superficial layers directly lining the surface of the 
bladder. It is also known as the umbrella cells stratum, with tight junctions on its surface. 
It is covered by a sheet of crystalline proteins called "uroplakins". Urothelium has an 
important role in bladder contraction and relaxation because it acts as sensory neurones. 
Urothelium contains receptors for different neurotransmitters such as nicotinic, 
muscarinic and adrenergic. When it is stimulated, it releases neurotransmitters. When the 
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bladder is filling with urine, it stretches without loosing its barrier property. This property 
is maintained by vesicles' movement from cytoplasm to the plasmic membrane of the 
umbrella cells, and by increasing the surface area of the cells. The trafficking of vesicles 
is mediated by cAMP, protein kinase A, and protein secretion (De Groat, 2004). The 
movement of vesicles is also accompanied by the release of nitric oxide (NO) and 
adenosine triphosphate (ATP) which bind to the receptors of sub-mucosa of the bladder 
(Fry et al., 2004). The sensory nerves located at that area of the bladder, generate input 
to the spinal cord. Other stimuli of the sensory nerves are hydrostatic pressure and pH 
change (De Groat, 2004). 
Innervations of the urinary bladder 
The urinary bladder is innervated by parasympathetic, sympathetic and somatic nerves. 
The central pathway is located in the brain, spinal cord and pons. 
Efferent nerves 
a. Parasympathetic fibres play a major role in the bladder function. It is formed by 
preganglionic fibres from central nervous system (CNS) and postganglionic fibres. The 
preganglionic fibres originate from S2-S4 (sacral outflow), and are responsible for the 
motor stimuli to the bladder. Activation of parasympathetic nerves induces contraction of 
the urinary bladder detrusor muscle. All preganglionic and postganglionic fibres release 
acetylcholine (ACh) as neurotransmitter, and are also called cholinergic neurones. The 
preganglionic neurones synapse with postganglionic fibres in ganglia that are situated 
within the bladder. 
b. Sympathetic fibres that innervate urinary bladder are derived from T10 to L2, and 
pass through superior and inferior hypogastric plexi in order to reach urethral sphincter. It 
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releases ACh by pre-synaptic fibres and noradrenaline by postganglionic fibers. 
Noradrenaline induces contraction of the bladder base and urethral smooth muscle via its 
action on vesicle and urethral ai -receptors. The action of noradrenaline on p2-receptors 
causes relaxation of the bladder's body (Moffett, 1993). 
c. Somatic nerves (skeletal motor fibres) 
These nerves originate from S2-S4, and pass through pudendal nerves to innervate 
skeletal muscles of external urethral sphincter. During voiding, there is inhibition of these 
nerves, which leads to relaxation of external sphincter. Somatic nerves release ACh, its 
action on nicotinic receptors induces contraction of external sphincter. This skeletal 
muscle also receives noradrenaline from sympathetic nerves. The combination of 
sympathetic and somatic actions increases resistance of urinary bladder outlet, which 
strengthens urinary continence (Souter, 2005). 
Afferent pathways 
When the bladder is full of urine, the fullness is conveyed to the spinal cord by afferent 
nerves. Afferent nerve fibres are sensitive to the pressure exerted by urine on the bladder 
walls, owing to tension receptors situated in the urothelium layer. The micturition reflex 
in humans is mediated by myelinated axons because unmyelinated fibers are 
unresponsive to chemicals or cold stimuli. When the bladder is filling, there is stretching 
of urothelium; this situation causes cellular changes in order to accommodate the 
increasing quantity of urine. Urothelium being a tissue with neurone-like properties, 
releases neurotransmitters such as ATP and NO that stimulate sub-mucosal afferent 




Blood vessels of urinary bladder 
The urinary bladder receives blood from the superior, middle and the inferior vesical 
arteries originating from the anterior trunk of hypogastric, the obturator and inferior 
gluteal arteries which branch from the vagina in the female. Vessels that drain blood from 
the bladder are those from plexi of the inferior surface and hypogastric area (Marieb, 
2004). 
Cytology of urinary bladder smooth muscle 
Smooth muscles are divided into two types, namely single unit- and the multi-unit 
smooth muscles. This study focuses on a single unit smooth muscle (SUSM), since it is 
the one found in the urinary bladder. SUSM contains fibres that have synchronous 
electrical and mechanical activities, and when it is stimulated, it contracts as a single unit. 
These fibres are attached to other adjacent cells by gap junctions: channels that facilitate 
the flow of ions from one cell to another, leading to the propagation of action potentials 
(AP). These gaps are formed by trans-membrane proteins known as connexins. The 
contractile response of the smooth muscles may be due to the stimuli brought by nerves, 
hormones and other factors such as heat and change in pH. When the smooth muscle 
stretches, it increases the luminary volume which may also induce contraction caused by 
reflex system stimulation. The smooth muscle is made of proteins that play a role in the 
urinary bladder contraction and relaxation, made of actin latices (formed by globular 
actin molecules); myosin filaments (contractile units); dense bodies and intermediate 
filaments that interconnect the dense bodies (Sugi, 1992). 
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Thin filament 
Thin filaments are mainly constituted by actin and tropomyosin, actin filaments itself 
being made by two stranded helix of actin monomers. Tropomyosin is found in the 
groove on either side of actin filaments (Berne and Levy, 2004). 
Myosin (thick filament) 
Myosin is made up of two pairs of heavy chains formed by a head and a tail structure that 
assumes a filamentous form during the contraction-relaxation process (Fozzard and 
Jennings, 1991). The cross bridge between actin and myosin occurs at the region of the 
head of heavy chain. 
Calmodulin 
This is a cystosolic protein that contains four Ca binding areas. The binding induces 
molecular conformational changes and becomes activated, ready to bind to the target cell 
(Sugi, 1992). 
Myosin light chain kinase 
This is an enzyme that depends on calcium-calmodulin complex to get activated. It 
regulates the phosphorylation of the light chain present on the head of the myosin (Berne 
and Levy, 2004). 
Dense bodies 
Dense bodies play a role of actin anchorage site; the same role is played by Z-line in 
skeletal muscles. In smooth muscles, contractile apparatus is not organized into 
myofibrils; instead, they are simply replaced by dense bodies in myoplasm. In 
sarcolemma, dense bodies are attached to one another as patches on the inner side of 
plasma membrane (Berne and Levy, 2004). 
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Sarcoplasmic reticulum (SR) 
SRs are small diameter sarcotubules that surround the myofibrils'. They have no basement 
membrane, and are often close to the surface of sarcolemma where they form dreads. SRs 
extend throughout the cell, and at some points, abut regions of sarcolemma (Sugi, 1992). 
Intermediate filaments 
These filaments are made up of insoluble proteins that form the skeletal frame-work of 
cytoplasm. They are divided into two different forms: (a) filaments that contain actin, 
desmin and filamin; and (b) filaments that contain actin, myosin, caldesmon and 
tropomyosin (Berne and Levy, 2004). 
Gap junction 
They are responsible for electrical and chemical communications by diffusion of low 
molecular weight compounds, and facilitate the propagation of action potentials (AP) 
from one cell to another (Bullock et al, 1995). 
Caveoli 




PHYSIOLOGY OF URINARY BLADDER 
Peripheral nervous system 
In this section, the nervous system will be described because it is one of the components 
that play a crucial role in urinary system. The description made focus on the autonomic 
nervous system in order to understand the functions of the urinary bladder. I will also 
examine three components of the nervous system: parasympathetic, sympathetic and 
somatic nervous systems. Parasympathetic and sympathetic nervous systems are known 
as autonomic nervous or involuntary nervous system because they are not controlled by 
will. 
The contraction of urinary bladder and relaxation of internal sphincter are involuntary 
actions. On the contrary, the skeletal muscle that plays the role of external sphincter is 
controlled by the brain, thus voluntarily controlled (somatic innervations). 
Parasympathetic nervous system 
Parasympathetic nervous system is made up of pre- and post-ganglionic fibres. The pre-
ganglionic fibres originate from CNS (midbrain, medulla oblongata and spinal cord). The 
parasympathetic fibres that innervate the urinary bladder are those from sacral area of the 
spinal cord. They pass through pelvic nerves before synapsing with post-ganglionic 
nerve, and abut to the urinary bladder. The pre-ganglionic fibers are longer than the post-
ganglionic ones which cause the innervated organs to lie near the ganglion. 
The parasympathetic nervous system plays an important role in energy conservation and 
maintenance of organ function when less energy is required. The pre- and post-ganglionic 
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nerves release acetylcholine, respectively, in ganglion and in the neuro-effector junction 
of innervated organs (Rhoades and Pflanzer, 1989). 
Synthesis of acetylcholine (ACh) 
Acetylcholine is synthesized from acetyl co-enzyme A and choline by an enzyme called 
choline acetyltransferase. Acetyl co-enzyme A is a compound formed during glycolysis, 
catalysed by pyruvate dehydrogenase. This synthesis takes place in the mitochondria, and 
then transported by citrate into cytoplasm where the complex is hydrolyzed by citrate 
lyase. After its synthesis, ACh is stored in synaptic vesicles. This process requires energy 
that is provided by ATPase, which pumps proton inside the vesicle. The release of H+ 
from the vesicles provides the required energy for the uptake of ACh. ACh base being 
positively charged, ATP and heparin sulphate proteoglycan help in the molecular 
neutralization, and thus, facilitate the packaging (Rang, 2003). 
The release of ACh 
When an action potential reaches the end of efferent nerves, there is a release of ACh as a 
result of fusion between synaptic vesicles with plasma membrane following 
depolarization that opens Ca +-dependant channels. This synaptic transmission is also 
known as electrochemical transmission that allows ACh to be released into synaptic cleft, 
and to bind to nicotinic receptors that are present in ganglions. The binding of ACh to 
postsynaptic receptors causes stimulation of postsynaptic neurones, called "direct ligand-
gated conductance". When two ligands bind to a nicotinic receptor, they cause a change 
in conformation, followed by the opening of ionic channel that is selective to K+and Na+, 
and depolarization of the postsynaptic neurons. The duration of the binding is limited to 
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less than 10 ms, and ACh is degraded by acetylcholinesterase (AChE) (Goodman and 
Gilman, 2001). 
Acetylcholinesterase (AChE) 
Acetylcholinesterase is an enzyme involved in the degradation of ACh. There are two 
types of AChE, namely: (i) acetylcholinesterase or true cholinesterase, and (ii) butyl-
cholinesterase (BuChE) that is also known as 'pseudo-cholinesterase' (Goodman and 
Gilman, 2001). The first one is formed by simple homeric oligomers in catalytic subunits, 
while the other one is formed by heteromeric catalytic subunits. The mode of action of 
AChE resides in its ability to hydrolyze ACh, thus reducing the action of Ach (Golan et 
al, 2005). 
Activation of nicotinic receptors at neuro-muscular junction 
The binding of ACh to nicotinic receptors of a cell membrane causes depolarization of 
the motor-end-plate, and triggers muscle contraction. ACh also binds to different types of 
muscarinic receptors, and causes different outcomes according to the organs concerned 
(Goodman and Gilman, 2001). 
Physiology of cholinergic transmission 
The parasympathetic system is mainly formed by neurones that discharge discrete and 
localized neurotransmitters. Its role is to maintain the organ's function and energy 
conservation during the period of low activity. Parasympathetic nervous system 
stimulation excites the GIT, reduces the heart rate, decreases the blood pressure and 
contracts the urinary bladder smooth muscle. In order to assume that task, the post-
synaptic neurons release ACh to innervated organs (Golan et al., 2005). 
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Steps in ACh transmission 
It is important to understand the steps involved in ACh transmission because they help in 
understanding ACh regulation. When the axon is at rest, its interior is about -70mv 
compared to its exterior. This difference in potential is maintained by the high 
concentration of K+ in the axoplasm. The extracellular area is highly concentrated in Na+ 
and CI" ions. The gradient of these ions is maintained by the active transport that requires 
energy from ATP by Na+/K+ATPase. During depolarization, there is initiation of action 
potential (AP) by increased permeability of axonal membrane to Na+ through voltage-
sensitive Na+ channels. Inside the axon, there is an increase in positive charges. The 
second phase involves the closure of Na+ channels, and the delayed opening of K+ 
channels that allows K+ to leave the axon. Depolarization is maintained by constant 
inward movement of Ca2+ ions; all three events initiate electrical circuit in the axon, 
which, in turn, propagates to the area of axon that was not previously affected. When the 
action potential reaches the axonal terminal, it causes excitation or inhibition on synapse 
or effectors organs (Goodman and Gilman, 2001). 
Nicotinic ACh receptors 
Nicotinic ACh receptors are known to be ligand-gated ionic channels. When they are 
activated, they cause an increase in permeability of host cells to Na+ and Ca2+. The 
sequence of their amino acids have been found by the process of molecular cloning which 
has revealed the existence of two species of nicotinic receptors that belong to different 
families of proteins. They exist in a pentameric form, comprising one to four different 
subunits built around an ionic channel. Nicotinic acetylcholine receptors are molecules 
that weigh about 280 KDa, and are made of five subunits that form a central channel. 
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Because of the similarity with GABA, serotonin and glycine receptors, they are in one 
group called "nicotinoid receptor family". Nicotinic receptors have twelve subunits made 
up of a and P units that combine together to make a pentamer. For example, nicotinic 
receptors on skeletal muscles comprise of four different subunits (o^pSy or 0i2(35£ ). 
When ACh binds to these receptors, there is initiation of end plate potential (EPP) and 
excitation of postsynaptic potential in the neurone (EPSP) (Goodman and Gilman, 2001). 
Muscarinic receptors 
Five subtypes of muscarinic receptors have been identified, using DNA clonic method 
(Eglen and Nahorski, 2000). 
These five muscarinic subtypes are differently localized in the body. 
The pharmacological classification of muscarinic receptors is based on selectivity of 
agonists and antagonists. McNA343 and oxotremorine display selectivity to M\-
receptors, and among antagonist, pirenzepine is selective on Mi-receptors. Mi-receptors 
are found mainly in CNS and in peripheral neurons of gastric parietal cells. They are also 
found in ganglia and in secretory glands. Mi, M3 and M5 subtypes exert their activity by 
stimulating G-protein called Gq/u coupled to phosphatidyl inosital polyphosphate of cell 
membranes, resulting in formation of inositol polyphosphates. This process leads to the 
release of Ca2+ from endoplasmic reticulum, which initiates the contraction of smooth 
muscles. Another product of hydrolysis is diacyl glycerol (DAG), which activates protein 
kinase C. 
- M2- and M4-muscarinic receptor activations lead to interactions of the receptors with 
G-proteins ( Gi and Go), resulting in inhibition of adenylate cyclase (AC), activation of 
receptor-operated K channels, and suppression of the activity of voltage-gated Ca 
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channels (Uustare et al.,2003). The a-subunits of G-protein (Gi) possess the following 
subtypes ai (aii, 0U2, oris). When M2 mACh R is stimulated, adenylate cyclase previously 
stimulated becomes inhibited through activation of Gi proteins (Uustare et al., 2004). 
The contraction of urinary bladder is mediated by parasympathetic nerves through the 
binding of ACh to M2 and M3 receptors (Tong and Cheng, 1990). Studies on bladder 
dome have revealed that M2 receptors are more in number compared with M3, but the 
contractile response of detrusor muscle is mediated mainly by M3-receptor subtype 
{G\g\\o et al, 2001). 
Interaction between M2. and M3.receptors 
It has been shown that M3-receptor stimulation has a direct contractile effect on bladder 
smooth muscles through mobilization of Ca inside the smooth muscle cells, while M2-
receptor action is mediated through M3-receptor potentiation (Ehler, 2003). M2-receptor 
stimulation may also potentiate other Ca mobilizing receptors, which suggests that M2-
receptors alone cannot mediate a direct contraction of smooth muscles because those 
contractions require Ca2+ mobilization. The inhibition of cAMP production through M2 
receptor stimulation leads neither to calcium mobilization nor to direct contraction of 
smooth muscles. Because M2-receptor stimulation can inhibit p-adrenoreceptor-mediated 
effect that leads to c AMP production, thus, inhibition of smooth muscle contraction, it is 
clear that M2-receptors can stop inhibition of contraction resulting from the relaxant 
effects generated by P-adrenoceptor activation. This is why contractions generated by 
stimulation of M2- and M3-receptors in the presence of P-agonist are far stronger 
compared to the contractions generated by activation of M3-receptors alone. When a 
94- • • • 
smooth muscle is at rest, the Ca concentration inside its cells is low; therefore, little 
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effect will be attained by stimulation of M2-receptors because this effect is supposed to 
result from Ca2+ mobilization. But if M3-receptors are stimulated first, there will be Ca
2+ 
mobilization, and then stimulation of M2-receptors will generate contraction through 
stimulation of ionic conductance Icat and BKca (channels that depend on K
+ and Ca2+ 
respectively, in order to open and close). Calcium mobilization will stop the efflux of K+, 
and thus inhibit relaxation. This observation may be the explanation for the fact that 
contraction of urinary bladder is due to the stimulation of M3-receptors, even though 
studies on urinary bladder dome revealed that the density of M2-receptors is higher than 
that of M3-receptors, and the contractile action of the bladder is being triggered through 
M3-receptor stimulation. When competitive, selective antagonists on muscarinic 
receptors are used, the blockade of contractions is consistent with M3-receptor blockade 
instead of M2-receptors, but when non-selective antagonists are used, contractions that 
result from stimulation of M2- and M3-receptors together are far greater than the response 
obtained from stimulation of M3-receptors alone (Ehlert, 2003). The studies of Giglio et 
al. (2001) and Ehlert (2003), suggest that other neurotransmitters, apart from 
acetylcholine, are involved in detrusor muscle excitation because, atropine, which is a 
non-selective muscarinic receptor antagonist, failed to inhibit totally, contractions of 
urinary bladder. It has been found that purine nucleotide ATP, with its action on P2-
purinoceptors, may be responsible for contractions that are resistant to atropine's 
inhibitory effect. Adenosine, a purine nucleoside from ATP, causes relaxation of detrusor 
muscle via subtype Ai or Pr purinoceptors. It is now clear that contraction and relaxation 
of urinary bladder smooth muscles are caused by interaction of numerous substances that 
act on different receptors. Because ATP is co-released with acetylcholine in the 
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parasympathetic nervous system innervating urinary bladder, and its metabolite, 
adenosine, has a relaxant effect on urinary bladder detrusor muscle, it can be assumed 
that ATP has an indirectly relaxant effect on urinary bladder. This is probably why when 
ATP is administered to an isolated urinary bladder; it causes an initial contraction 
followed by a long duration relaxation. These relaxations can be terminated by adenosine 
receptor antagonists. In this scenario, M3-receptor stimulation may interfere with the 
relaxant effect of cAMP produced during stimulation of purinergic receptors by 
adenosine. The effect of M3-receptors is largely due to activation of adenylate cyclase. 
The role of G-proteins 
G-proteins are molecules that interact with guanine nucleotides GTP and GDP. They 
consist of 3 subunits a, p and y. When guanine nucleotide (GTP) binds to an a-subunit, 
there is conversion of GTP to GDP, while p y- complex remains unchanged. The three 
subunits are attached to phospholipids of the cell membrane, and are coupled to G-
protein by a reaction called 'phenylation'. When no ligand is attached to the receptor, the 
G-protein consists of unseparated aPy-complex with GDP attached to a-subunit. When an 
agonist settles on these receptors, there is a conformational change in cytoplasmic 
domain that becomes coupled to aPy-complex (Goodman and Gilman, 2001). This event 
allows GDP that was previously bound to the a-subunit to exchange with GTP, followed 
by dissociation of the aPy-complex into a-GTP and Py-complex (Golan et al., 2005). The 
newly formed fragments are active forms that are ready to diffuse and activate ionic 
channels and different proteins inside the cell. This action will be terminated by the 
hydrolysis of GTP to GDP, catalyzed by GTP-ase followed by reunification of a-GDP 
and Py-complex. The selectivity of G-protein is due to the difference in the affinity that 
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the various classes of G-proteins (Gi, Gs and Gq) have with respect to the receptors and 
the effectors involved. Activation of Gs and Gi leads, respectively, to the stimulation and 
inhibition of adenylate cyclase (Golan et ai, 2005; Rang et ah, 2003; Goodman and 
Gilman, 2001). 
Second messengers 
Second messengers are cytoplasmic compounds, whose synthesis, release and 
degradation are responsible for changes seen when ligands bind to G-protein receptors on 
cell membranes. In this section, attention will only be focused on cAMP, Ca2+, inositol 
phosphate, and diacylgycerol. All second messengers influence one another, which make 
their study more complex. 
1. cAMP and adenylate cyclase 
Cyclic adenosine monophosphate (cAMP) is a nucleotide that is synthesized in the cell 
by action of adenylate cyclate on adenosine triphosphate (ATP). Its existence is 
terminated by a group of enzymes called 'phosphodiesterases', which transform cAMP 
into 5'-AMP. cAMP is involved in regulating cellular functions such as ion transport, 
contraction of smooth muscle, and modulation of ionic channel. All these functions are 
due to its ability to activate protein kinases. Protein kinases use ATP as source of 
phosphate group in order to phosphorylate proteins' serine and threonine residues. In 
urinary bladder smooth muscle, protein kinase phosphorylates an enzyme involved in 
muscle contraction known as myosin light chain kinase. When the receptor linked to Gi is 
activated, they inhibit adenylate cyclase which leads to the reduction in cAMP synthesis. 
For example, stimulation of M2-receptors of urinary bladder detrusor muscle by 
acetylcholine leads to inhibition of adenylate cyclase (Rang, 2003). 
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2. Inositol phosphate and phospholipase C 
Inositol phosphate is a second messenger generated by the breakdown of membrane 
phospholipids. This messenger increases the concentration of intracellular Ca2+ in smooth 
muscles. Phosphatidyl inositol 4, 5-biphosphate (PIP2) is a substrate of PLCp, which 
dislocates into diacyl glycerol (DAG) and inositol 1, 4, 5- triphosphate (IP3) that 
functions as second messengers. IP3 triggers the release of Ca2+ from intracellular stores. 
IP3 being water soluble, acts on IP3 -receptors in cytosol, which is a ligand-gated calcium 
channel that exists on the endoplasmic reticulum membrane. Inside the cell, IP3 is 
converted into 1, 3, 4, 5-tetraphosphate (IP4) by a kinase. IP4 is involved in facilitating 
Ca2+ entry into cytoplasm. DAG, formed from PLCp, diffuses inside the cell membrane, 
and activates protein kinase C (PKC), which phosphorylates protein inside the cell. DAG 
is generated during hydrolysis of inositol phosphate, and is involved in the activation of 
membrane bound protein kinase, followed by phosphorylation of different intercellular 
proteins. Being a lipophilic compound, it is able to diffuse through the cell membrane. 
When GAD activates specific protein, there is an increase in intracellular Ca2+ 
concentration (Rang, 2003). 
Sympathetic nervous system 
In urinary bladder function, sympathetic neurones are derived from T i l , LI and 2, and 
they innervate internal sphincter. The action of noradrenaline on a-receptors causes 
contraction of urinary bladder sphincter. When noradrenaline is released by sympathetic 
neurones, its binding on (32-receptors of the bladder base causes relaxation (Vignes, 
2005). 
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Synthesis, action and degradation of noradrenaline 
Noradrenaline is a neurotransmitter released by sympathetic postganglionic neurons. It is 
synthesized from tyrosine by a series of reactions. Tyrosine reacts with tyrosine 
hydroxylase to give dopa. By the action of dopa decarboxylase, dopa is transformed to 
dopamine; the action of dopamine p-hydroxylase on dopa generates noradrenaline. 
Noradrenaline is changed into adrenaline by phenyl ethanolamine N-methyltransferase. 
The release of noradrenaline from vesicles is triggered by the arrival of action potential 
(AP) impulses which stimulate the discharge of Ca2+ into synaptic vesicles, followed by 
the release of noradrenaline (Golan et al., 2005) 
Beta-adrenergic receptors 
There are three types of p-adrenoceptors with similarities in 60% of their amino acid 
sequence. They are membrane spanning receptors, and noradrenaline binds to their 
external domain. The three P-adrenergic receptors stimulate adenylate cyclase by their 
interaction with Gs proteins. When these receptors are stimulated, there is accumulation 
of cAMP, followed by activation of protein kinase. Gs may also modulate the voltage-
sensitive Ca2+ channels. Stimulation of urinary bladder P2-receptors leads to relaxation 
caused by the increase in cAMP synthesis and release. The relaxation of this smooth 
muscle is also due to the extrusion of Ca2+ from muscle cells, and the binding of the 
remaining Ca2+ inside sarcoplasmic reticulum store (Culter et al., 1994). 
Alpha-adrenergic receptors 
Stimulation of a-adrenoceptors by agonists triggers mobilization of Ca2+ in the cytoplasm 
from endoplasmic reticulum stores by phospholipase C. Phospholipase C hydrolyses 
phosphoinositides to produce diacyl glycerol (DAG) and inositol-1, 4, 5-triphosphate 
19 
(IP3), which activate protein kinase C, followed by the release Ca from endoplasmic 
reticulum stores (Culter et al, 1994). 
Other neurotransmitters involved in urinary bladder function 
Adenosine Triphosphate (ATP) 
ATP is a co-transmitter in terminal nerves. In the urinary bladder, ATP is responsible for 
the bladder contractions initiated by parasympathetic nerves. Its action is blocked by 
suramin, which antagonizes ATP at its purinergic receptors (Giglio, 2001). When 
urothelium of the urinary bladder is stimulated by stretch, hydrostatic pressure or pH 
change, it releases ATP, which binds to purinergic receptors P2X, and mediates 
mechanosensory transduction in the bladder afferent nerves (Rang et al, 2003; Benko et 
al, 2003). 
Vanilloid receptors 
Vanilloid receptors are present in afferent neurones. They inherited this name on the basis 
of the fact that they are stimulated by capsaicin, an alkaloid found in chilli peppers, with 
vanillic acid structure (De Groat, 2004). Vanilloid receptors are sensitive to heat, pH 
variation (such as the transient receptor potential channel vanilloid receptor subunitl 
TRPV1). When TRPV1 is activated by heat above 50°C, it stimulates sensory neurones. 
Vanilloid receptors are also sensitive to mechanical stimuli, and their excitation is 
mediated by different cation channels (Golan et al, 2005). When an agonist such as 
capsaicin binds to these receptors, there is opening of Ca2+ and Na+ channels, followed by 
depolarization, resulting in the propagation of action potential (AP). Other compounds 
that act on vanilloid receptors are: anandamide and resiniferatoxin. When capsaicin is 
applied to urinary bladder, it causes degeneration of afferent nerve terminals (Fry et al, 
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2004). This is why it is used to treat incontinence (inhibition of C-fibers of afferent 
nerves). Stimulation of urinary bladder by capsaicin results in the release of nitric oxide 
(NO) mediated by calcium-dependant nitric oxide synthetase (Fry et al., 2004; Culter et 
al., 1994). 
Prostaglandins 
The epithelium of urinary bladder is not a passive barrier between the urine component 
and the blood. Contrary, it releases a second messenger such as PG (F2a; F2) and other 
non-prostanoic compounds that participate in the bladder function. Prostaglandins are 
second messengers that regulate the bladder's physiological and pathological functions. 
Increases in synthesis of prostanoid compounds, for example, in the case of epithelium 
irritation, causes hyperactivity of detrusor muscle. In diabetic rats, the amount of PGF2Q 
and PGF2 are greater compared to the urinary bladder of normal rats. Hyperactivity 
induced by the increase of prostanoic compounds can be treated successfully with 
indomethacin. This situation seems to be due to the direct action of prostanoic 
compounds in urinary bladder smooth muscle, rather than on sensory neurone endings. 
The PGF2a and PGF2 production is due to the cyclo-oxygenase 2-induced response to 
pro-inflammatory cytokinines and lipopolysaccharides (Yamaguchi, 2004). Prostaglandin 
in this case, is increased as compensation against diabetic neuropathy of motor and 
sensory nerves (Yamaguchi, 2004) 
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The micturition reflex 
Even if micturition reflex is an automatic action, in an adult person, it can be inhibited by 
the appropriate centre in the brain (the centre that is located in pons and cerebral cortex). 
The higher centre will inhibit micturition until the individual has a desire to urinate, and it 
may control and inhibit micturition even if there is a desire to urinate. In due time, the 
cortical centre will facilitate micturition reflex and inhibit contraction of external 
sphincter. Urine is brought in to the bladder by small smooth muscle tubes called ureters. 
They are innervated by both sympathetic and parasympathetic nervous systems. The flow 
of urine in the ureters is facilitated by peristaltic waves traveling along the ureters. When 
the bladder is empty, intravesical pressure is zero, and the pressure rises as the bladder 
progressively receives urine. As the bladder fills up with urine, micturition contraction 
starts to appear as a result of stretch of urinary bladder that stimulates the sensory 
receptor of the bladder wall. These sensory signals are brought to the spinal cord by 
pelvic nerves, and return to the bladder through parasympathetic fibres. The first 
contraction, self generated, induces further activation of receptors which cause increase 
in reflex contraction of the bladder; the scenario is repeated until the bladder has reached 
a high degree of contraction. The micturition reflex is a cycle made up of 3 phases: 
(1) progressive and rapid rise in internal pressure 
(2) constantly raised pressure, and 
(3) drop in basal tonic pressure of the bladder. 
When micturition pressure has not succeeded in emptying the bladder, the second reflex 
may come after a period of about 30 minutes to 1 hour. As the urine continues to flow 
inside the bladder, the contraction becomes more and more stronger, and often painful. 
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As micturition becomes stronger, another reflex is generated, and passes along pudendal 
nerves to the external sphincter in order to inhibit it. If the voluntary contractor signals of 
external sphincter from the brain cannot overcome pudendal reflex, involuntary urination 
may occur (Souter, 2005; Viges et al., 2005). 
Contraction of the smooth muscle of urinary bladder 
The urinary bladder smooth muscle functions as other smooth muscles found elsewhere 
in the body, with a slight difference in how it is stimulated. Smooth muscles in general, 
differ from skeletal muscles because the former is not under voluntary control. The 
structures of these two types of muscles differ also. Smooth muscles have no striation 
found in skeletal muscles. In urinary bladder, cells are irregularly shaped and bind 
together by intermediate junctions. At these junctions, cells are thick and separated by 
gaps that contain dense granular materials. Through these gaps, proteinous tubes connect 
adjacent cells, and give a passage to ions and small molecules. When urinary bladder 
smooth muscles are at rest, their cells have a membrane potential that is between -20 and 
65 mv. This resting membrane potential is maintained by the relative permeability of the 
cell membrane to ions through ionic pumps like Na+-K+ ATPase. The most important 
and useful channel in cell excitation is the voltage-gated calcium channel. This channel 
can be blocked by nifedipine or verapamil. Another channel that plays a role in the 
contraction of urinary bladder is the K+-channel. The membrane of the bladder cells also 
has Na+-Ca2+ exchange mechanism that allows calcium to enter into the cell, and to expel 
Na+ ions to outside of the cell. 
As indicated previously, smooth muscle cells contain thin, thick and intermediate 
filaments. The thin filaments contain actin, while the thick filaments contain myosin. 
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Intermediate filaments are made of proteins called 'desmin' and 'vimentin' in smooth 
muscle cells. Thin filaments are organized into bundles inserted through dense bodies, 
which play a role comparable to the one played by Z lines in skeletal muscles. Thin 
filaments that pass through dense bodies have opposite polarities at their two extremities, 
which allow them to react with myosin. As skeletal muscles have T-tubules that are 
useful in providing electrical links to the sarcoplasmic reticulum (SR), smooth muscles 
use alveoli that assume the same role. They increase the surface volume ratio of the cell 
where Ca2+ enters the cell through sarcolemma that contains voltage-gated calcium 
channels. SR is also a reservoir of free Ca2+ and plays a role in excitation-contraction (E-
C) coupling by regulating free Ca2+ concentration in the myoplasm. Ryanodine receptors 
(RyR) are important in assuming the role of ligand-gated, Ca-channels that are situated at 
the junctional area of SR, where Ca2+ is expelled after action potential (Frank and 
Bianchi, 1992). The release of Ca2+ from SR into myoplasm can be induced by 
neurotransmitters, hormones or drugs that bind to receptors on the sarcolemma. 
Ryanodine receptors are activated by an increase in intracellular Ca . Its release from SR 
is important in balancing the concentration of free Ca2+. It is a physiological regulation 
in which free cytoplasmic Ca is kept at a controlled level in the centre of SR, and at the 
junction of SR with plasma membrane. Contrary to skeletal muscles where Ca2+-
dependant channels can be opened potentially to release Ca2+ from T- cells, in smooth 
muscles, the release of Ca2+ from SR must be initiated by chemicals (Sugi, 1992). 
Contractions are produced by Ca2+ entry through voltage- or ligand-gated Ca2+ channels, 
or by Ca2+released from SR initiated by IP3 (Frank and Bianchi, 1992; Rang et al., 2003). 
Contraction of smooth muscles is generated when the myosin light chain is 
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phosphorylated by myosin light chain kinase, leading to its separation from actin 
filaments. This process of phosphorylation is catalyzed by myosin light chain kinase, and 
activated by Ca2+-calmodulin complex. Myosin light chain kinase catalyses the 
phosphorylation of myosin P light chain, leading to the activation of myosin by actin. The 
end result of this series of reactions is the cross bridge and sliding of filaments, resulting 
in muscle contraction. During the interaction between phosphorylated light chain myosin 
and actin, ADP and inorganic phosphate (Pi) are liberated from myosin, allowing ATP 
formation. ATP reduces the affinity of myosin to actin, followed by the release of myosin 
from actin. Energy released in this process is used to change the conformation of myosin 
head, and another cycle of contraction is ready to start (Berne and Levy, 2004). 
Relaxation of smooth muscles requires a second enzyme called 'myosin phosphatase', 
which reverses previous phosphorylation. 
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CHAPTER THREE 
Diseases of the urinary bladder 
1. Cystitis 
Cystitis is an inflammation of the urinary bladder that may be the result of bacterial 
infection, or intestinal cystitis which is not caused by infection. When it is caused by 
infection (normally a coliform bacterium transmitted from the bowel to urinary bladder 
passing though urethra), it may be treated by antibiotics and the patient is advised to 
drink a lot of fluid which helps to flush out the remaining of unkilled bacteria from the 
bladder, then the bladder may recover after a certain period of time. Drugs that increase 
urinary pH, such as potassium citrate, are also given to the patient in order to relieve 
symptoms. 
Hemorrhagic cystitis is an inflammation of the bladder that may result into hemorrhage. 
It may be caused by chemotherapy, viral infection, or radiations. 
Intestinal cystitis is a disease of urinary bladder which causes intense pain of the bladder 
and the pelvis in general. It also induces frequent urination and painful sexual 
intercourse. It is caused by autoimmune factors, neurologic, genetic and allergic 
conditions. It damages the protective layer of the bladder (Rosamilia and Franzog, 2005). 
Treatment of interstitial cystitis involves modification of diet (avoid irritants), bladder 
coating (astringent, e.g. silver nitrate that kills infecting agents), antihistamines that 
control the released histamine from mast cells, and the use of antidepressants such as 
amitryptiline, that stop neuro-inflammation. When interstitial cystitis is caused by pelvic 
floor dysfunction, the treatment will be to relax pelvic floor muscles. 
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2. Ureterocele 
Ureterocele is a congenital abnormality of the urinary bladder that involves the distal 
ureter in the opening to the bladder. The patient may present with the following 
symptoms: urinary retention, haematuria, abdominal pain and urethral calculus. The 
cause of ureterocele is not yet well identified. If it is not treated, however, it may lead to 
kidney stones formation, increased uric acid stones, and poor kidney function (Gotta et 
ah, 1998). 
3. Urinary bladder incontinence 
Incontinence is an involuntary excretion of urine. There are many types of urinary 
incontinence (Michel et ah, 2005): 
a. Urge incontinence 
It is an involuntary urination which occurs without any reason. It results from 
contractions of urinary bladder detrusor muscles. It includes idiopathic detrusor over-
activity and neurogenic detrusor over-activity. This incontinence normally occurs when 
the patient has taken fluid before going to sleep. Contractions of the bladder may occur 
because of the damage to the neurones that innervate urinary bladder, or to the spinal 
cord. This damage may be caused by surgical operation, Alzheimer's disease, and so on. 
b. Stress incontinence 
This is an incontinence that results from an increased internal pressure from coughing, 
laughing, exercising, or even pregnancy. In females, it may be caused by a decrease in 
oestrogen that occurs before menstrual period. This decrease lowers the force of urethral 
sphincter, resulting in leakage. This kind of incontinence may be aggravated by 
menopause. 
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c. Overflow incontinence 
When the bladder is full of urine, it may leak as a result of the weakness of urinary 
bladder detrusor muscle that is not able to empty the bladder completely. Blockade of 
urethra may be responsible for this type of incontinence. Diabetic autonomic neuropathy 
may also cause overflow incontinence by the mechanism already explained earlier. 
Treatment of urinary bladder incontinence 
Several options are available to treat urinary bladder incontinence. They include exercise, 
electrical stimulation that strengthens the muscles of lower pelvis, bladder training, and 
medications such as oestrogen, oxybutynin, darifenacin, propantheline, tolteroline, 




Definition — Diabetes mellitus is a group of hormonal and metabolic syndromes 
characterized by hyperglycaemia and altered metabolism of lipid, carbohydrates and 
proteins (Goodman and Gilman, 2001). "Diabetes" means in Greek "pass through"; and 
"mellitus" "honeyed or sweet". It is named diabetes mellitus because patients with 
diabetes mellitus produce urine that contains sugar. This syndrome results from relative 
or absolute lack of insulin. It may also result from relative insufficiency of insulin 
production, or insulin resistance. 
Another type of diabetes is called 'gestational diabetes': It occurs during pregnancy, and 
it is caused by resistance of the body cells to insulin. The increase in glucose is 
sometimes proportional to the increase in foetal weight (polyhydramnios). There are two 
main types of diabetes mellitus, known as 'type 1' (or juvenile onset, insulin-dependent 
diabetes mellitus, i.e., IDDM) and 'type 2' (or adult/maturity onset, non-insulin-
dependent diabetes mellitus, i.e., NIDDM), respectively. 
Diagnosis 
The diagnosis, in the first instance, is clarified by some symptoms such as polyuria, 
polydipsia and polyphagia that become increasingly worse as the disease progresses. 
Screening of the blood will reveal high glucose concentrations than normal (>5 mmol/L). 
Confirmation of diagnosis requires the fasting blood glucose testing, and insulin and 
glucose tolerance testing. Some risk factors are associated with diabetes, and may guide 
physicians in its diagnosis. These factors are: high blood pressure, coronary artery 
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diseases, hepatic stenosis, and so on. Patients who are on chronic medication with 
glucocorticoids and/or thiazide diuretics may also develop diabetes mellitus (Shargel et 
ai, 1997). 
Aetiology 
Type 1 diabetes mellitus is usually caused by immunological and environmental factors, 
while type 2 diabetes mellitus is caused by endocrine disorder, pancreatic disease, drugs, 
genetic and environmental factors. 
Laboratory results 
A patient is classified as diabetic, when his/her fasting blood glucose measurement gives 
a concentration greater than 7.0 mmol/L or when his/her random blood glucose 
measurement gives results that are greater than 11.0 mmol/L. The higher concentration of 
the patient's blood glucose must be obtained more than once in order to qualify him/her 
as diabetic. In order to measure the patient's compliance to the treatment, it is necessary 
to check the level of glucose bound to haemoglobin (glycosylated hemoglobin, HbAic). 
When the result (HbA]c) is >7%, it means that the patient has not been compliant for the 
last three months (Shargel et al, 1997). 
Diabetic ketoacidosis (DKA) 
Diabetes ketoacidosis (DKA) is one of the complications caused by uncontrolled diabetes 
mellitus, and is a medical emergency. DKA is accompanied by dehydration, abdominal 
pain, lethargy and coma. This complication is experienced by type 1 diabetic patients 
who totally lack insulin necessary to protect the degradation of fatty acid. Some type 2 
diabetic patients may also experience DKA as their diabetic state becomes worse, 
because the pancreas may stop to produce insulin. In type 2 diabetic patients, a similar 
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complication called "hyperosmolar diabetic coma" occurs. Elevated blood glucose drives 
out water from cells into blood steam and finally reaches the kidney where it is 
eliminated with urine. High blood glucose concentration will exacerbate dehydration, 
increase in blood osmolarity, electrolyte imbalance, and coma (Shargel et ah, 1997). 
Complications of diabetes 
Chronic complications of diabetes affect different organs of diabetic patients when 
glycaemia has not been well controlled. These complications are classified into two 
groups according to their locations: macro- and micro-angiopathy. When complications 
result from small vessels, they lead to the following complications: 
- retinopathy (damage to retina) that may lead to blindness 
- peripheral neuropathy that causes foot ulcers, and 
- diabetic nephropathy that causes kidney failure. 
When complications result from large vessels, the patient may experience ischaemic heart 
diseases (condition that is caused by imbalance between oxygen demand and supply to 
the myocardium). Diabetes mellitus can also be caused by genetic factors, P-cells defect, 
and peripheral insulin receptor defect that lead to insulin resistance. While type 1 DM is 
caused by genetic, environment and autoimmune diseases; type 2 diabetes is caused by 
other conditions such as endocrine disorders, pancreatic disease, pregnancy or drugs such 
as thiazide diuretics and corticosteroids. Insulin reduces the amount of blood glucose by 
inhibiting its production by the liver, stimulating its uptake and metabolism in skeletal 
and adipose tissues (Vinik et al., 2003). 
31 
Anatomy of the Pancreas 
The pancreas is an organ that has exocrine and endocrine glands. The endocrine gland is 
also called 'Islets of Langerhans' which has three types of secretory cells, namely: a-cells 
that secrete glucagon, /?-cells that release insulin, and 8-cells that secrete somatostatin and 
gastrin. Glucagon promotes glycogenosis, gluconeogenesis and lipolysis of adipose 
tissues. Insulin promotes uptake of glucose, amino acids and fatty acids. It increases 
glycogen synthesis and storage in the liver from glucose. Somatostastin regulates the 
release of insulin and glucagons. It decreases the motility of gastrointestinal tract and 
growth hormones secretion. In the fed state, carbohydrates are broken down into glucose, 
fructose and galactose by gastrointestinal tract enzymes. These simple sugars are 
transported actively and passively by basal membrane transporters from epithelial cells 
into capillaries. When glucose reaches the blood stream, it is taken up into pancreatic /?-
cells. The increased concentration of glucose inside P-cells stimulates the release insulin 
that diffuses into portal vein, where it is transported by blood into the liver at the same 
time with digested food. Insulin thus secreted acts on tissues that store energy, such as 
liver, skeletal and adipose tissues. In the fasting state, glucose concentration decreases, 
pancreatic a-cells release glucagon, and pancreatic /?-cells reduce the amount of insulin 
secreted. Glucagon mobilizes glucose from the liver by increasing glycogenosis and 
gluconeogenesis. When the individual continues with fasting, catecholamine and 
glucocorticoid concentrations increase. This situation leads to the release of fatty acid; 
break down of protein and adipose tissue (Golan et al., 2005). 
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Insulin synthesis and secretion 
Insulin is synthesized in endoplasmic reticulum of pancreatic P-c'ells as a preproinsulin. It 
is then transported to Golgi apparatus where it is cleaved by proteolytic enzymes into 
insulin and c-peptide. The quantity of insulin to be released is proportional to the 
concentration of glucose in the blood. Two phases of insulin release are rapid secretion 
of stored insulin, and delayed secretion of synthesized insulin. This response is impaired 
in a diabetic patient (Goodman and Gilman, 2001). 
Secretion 
When pancreatic /?-cells are in contact with glucose, there is an increase in the ratio of 
ATP/ADP that stimulates insulin release. Glucose enters /?-cells down concentration 
gradient, and gets phosphorylated by hexokinase into glucose-6-phosphate, then enters 
into glycolytic cycle that ends up by citric acid and ATP increases. This ratio modulates 
the activity of ATP-sensitive K+ channel. The opening of this channel hyperpolarizes the 
cell by increased outward of K+. This channel is inhibited by ATP, and activated by 
ADP. The increased ATP/ADP ratio inside the cells shuts K+-channel, and induces 
depolarization followed by activation of voltage-gated Ca2+-channel. The increase in 
intracellular Ca2+ stimulates insulin release. In the case of low glucose, K+-channel 
remains open because of insufficient ATP/ADP ratio, and /?-cells will be in 
hyperpolarized state, which inhibits Ca2+entry into the cells. Without influx of Ca2+ inside 
the cells, vesicles that contain insulin will not be able to release insulin. When insulin is 
released from vesicles of /?-cells, it binds to receptors of target cells that exist on the cell 
membrane. A high density of insulin receptors is located on the surface of energy-storing 
tissues such as liver, adipose tissue, and striated muscles. These receptors are made up of 
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a- and /?- subunits, located at the cell surface. Two a-subunits are exclusively located at 
the surface of all membranes, while two /?-subunits are transmebranous; one portion 
being outside, and the other one inside the cell membrane. When insulin binds to these 
receptors, it activates the tyrosine kinase domains of /?-subunits, leading to receptor's 
autophosphorylation that initiates a cascade of reactions resulting in glucose transport, 
protein and glycogen synthesis. Insulin is also involved in visceral growth by stimulating 
cell proliferation (Golan et al., 2005). 
Glucagon synthesis and secretion 
Synthesis of glucagon 
Glucagon synthesis occurs in a-cells of the pancreas, and a small quantity is also 
synthesized in the upper part of GIT. Glucagon synthesis is stimulated by increased 
concentration of amino acids, especially arginine. Its secretion is induced by a protein 
meal, and a low concentration of blood glucose. When it is released from a-cells, it 
increases blood glucose concentration. It has the same action as /^-adrenergic compounds; 
and acts on specific receptors to stimulate adenylate cyclase (Goodman and Gilman, 
2001). 
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Treatment of Diabetes mellitus 
Patients with type 1 diabetes mellitus must be treated with insulin. The insulin dose 
should be calculated on the basis of the patient's weight, and his/her plasma glucose 
concentration. 
Management, control and/or treatment of type 2 diabetes mellitus 
1. Sulphonylureas (e. g., ghbenclamide) 
Sulphonylureas are also called "insulin secretagogues". Sulphonylureas such as 
ghbenclamide and gliclazide, stimulate insulin release from pancreatic |3-cells. They 
inhibit K+/ATP-channel, and they also increase insulin release by displacing Mg2+-ADP, 
which activates K+/ATP-channel. Because of their insulin release stimulation, 
sulphonylureas cause hypoglycaemia as their major side-effect. By their action on 
adipose tissues, sulphonylureas may cause patient's weight gain (Shalgel et al., 1997). 
2. Biguanides (e. g., metformin). 
The major action of biguanides is to increase insulin sensitivity by their action on 
adenosine monophosphate-dependant protein kinase (AMPPK). Biguanides activate 
AMPPK to block fatty acid degradation and gluconeogenesis. They also increase the 
sensitivity of insulin at the receptors. By decreasing the formation of glucose from fatty 
acid metabolites, they cause lactic acidosis as side-effect (Das et al., 1996). 
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3. Thiazolidinediones (e. g., rosiglitazone) 
These compounds decrease blood glucose by increasing insulin action at its receptors. In 
diabetic patients, the level of glucagons may be elevated, a situation that opposes the 
effect of insulin because glucagons stimulate glycogenolysis and gluconeogenesis (Das et 
al, 1996). 
Complications of diabetes mellitus 
When diabetes mellitus is not well controlled, it causes complications that involve several 
organs and systems. Some complications are acute, while others are chronic. 
Acute complications 
- diabetic ketoacidosis (DKA) 
- hyperglycaemic hyperosmolar non-ketotic coma (HHNC) 
Chronic complications 
- cardiovascular diseases 
- ocular complications 
- diabetic nephropathy 
- skin and mucous membrane complications, and 
- diabetic neuropathies 
The focus here will be on diabetic neuropathy, because it is linked to the objective of the 
present my study. 
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Diabetic autonomic neuropathy (DAN) 
Diabetic autonomic neuropathy is a complication that results from uncontrolled diabetes 
mellitus. This complication is not well understood, even though it has a negative impact 
on the quality of life of diabetic patients. It is also one of the conditions that increase 
medical expenses, and long duration of hospitalization. DAN can involve all ANS, motor 
or sensory nerves. This condition may involve one or more organs at a time, and may be 
clinical or sub-clinical. Here are some of the organs involved: 
- cardiovascular system 
- sudomotor 
- ocular, and 
- genito-urinary system 
When the vagus nerve is affected, because of its widespread nature in the body, DAN 
may cause a great damage to many organs at a time (Niakan et al., 1986; Vinik et al., 
2003). 
Epidemiology 
Diabetes neuropathy is a common complication of uncontrolled diabetes mellitus. It is a 
big cause of morbidity and mortality, with its prevalence of 20% in diabetic patients. It is 
also a cause of 75% amputation that results from non-traumatic causes. Hyperglycaemia 
is the main risk factor, and diabetes neuropathy is proportional to the duration of diabetes, 
age, hypertension and hyperlipidemia (Goodman and Gilman, 2001). 
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Pathology and Pathogenesis 
Factors that are involved in the development of diabetic neuropathy are: microvascular 
diseases, protein kinase C, polyol pathway and advanced glycation end product (Vinik et 
al., 2003). 
Aetiology of diabetic autonomic neuropathy 
1. Microvascular diseases 
There is interdependence between blood vessels and nerve functions because the 
functions of blood vessels are controlled by nerves, and nerves are fed with oxygen and 
other nutrients by the blood carried in the vessels. Microvascular vasoconstriction, when 
it is not treated, causes nerve damage that results into neuronal dysfunction because of 
reduced blood supply around neurones and inevitable hypoxia. Neuronal ischaemia is one 
of the characteristics of diabetes neuropathy, and one of the clinical changes seen in 
diabetic patients with uncontrolled diabetes (Niakan et al., 1986). 
2. Protein kinase C (PKC) 
Protein kinase C is an enzyme that adds phosphate groups to other proteins. This addition 
causes a functional change of the substrate. PKC is one of the enzymes that regulate 
cellular functions such as signal transduction. It removes inorganic phosphate from ATP 
and attaches it to hydroxyl group of amino acids (serine, tyrosine, and threonine). Its 
activity is turned off or on respectively, when it binds to protein inhibitor or protein 
activator. PKC is one of the proteins implicated in diabetic neuropathy because, the 
increase in blood glucose level leads to activation of diacyl glycerol, followed by 
activation of PKC that reduces nervous conductivity and blood flow around neurones 
(Vinik et al, 2003). 
38 
3. Advanced glycated end-products 
When there is a high level of glucose inside the cell, this condition may lead to the 
establishment of covalent bond between glucose and cell proteins, resulting in alteration 
and inactivation of targeted proteins. Because of the change in structure, this also 
exacerbates diabetes neuropathy (Beshay, 2004). 
4. Polyol pathway 
This pathway is also known as sorbitol-aldose-reductase pathway. It is a pathway that 
generates products involved in damaging micro-vessels that supply blood to nervous 
tissues. When blood glucose is high, there is activation of other biochemical pathways 
that have, as a consequence, reduction in glutathione and formation of oxygen radicals, 
by the action of enzyme called aldose reductase. Normally, body cells need insulin in 
order to utililize glucose, except retinal neuronal tissue and kidney cells. This means that 
without insulin, these glucose-dependent cells will continue to use glucose to produce the 
required energy. Excess glucose will be pushed into polyol pathways to generate sorbitol. 
As the level of blood glucose increases, the affinity of aldose reductase for glucose will 
also increase, stimulating the production of more sorbitol, and reduction in the level of 
NADPH. Sorbitol, being hydrophilic, cannot enter the cells easily, and its accumulation 
causes water retention. NADPH is involved in nitric oxide (NO), glutathione and 
fermentation of oxygen molecules. NO is a vasodilator of blood vessels, while 
glutathione protects cells against haemolysis resulting from oxidative stress. 
Nicotinamide adenine dinucleotide (NAD+) which is also produced in the pathway, plays 
a role in preventing the formation of reactive oxygen species (ROS) that damage the 
cells. Consequently, when there is activation of polyol pathway, there is damage to the 
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vessels that supply blood to the kidney, retina and the neurones. Diabetic autonomic 
neuropathy (DAN) has not only one cause; it has a complex aetiology, among which are: 
- autoimmune damage of neurones; 
- deficiency in neuro-hormonal growth factors; and 
- metabolic insult to nerve fibres. 
Diabetes mellitus being a condition manifested by increased blood glucose, activates 
polyol pathway that causes an increase in the amount of sorbitol, and an imbalance in 
NAD: NADH ratio. This leads to the damage of neurones, and to a reduced blood flow. 
This situation is complicated by activation of protein kinase C that further causes 
vasoconstriction and reduction of blood flow around neurones. There is also an increased 
amount of free radical production, which reduces NO production and endothelium 
damage. When there is a reduction in neurotrophic growth factors, reduction of fatty acid 
and advanced glycosylation end-products, all these situations participate in the reduction 
of blood flow, leading to hypoxia that further damages neurones (Beshay and Carrier, 
2004). 
Clinical manifestations of DAN 
All diabetic patients must be screened in order to assess the progression of DAN because 
sometimes the patient may be in a sub-clinical state of the complication. Here are some 
complications classified according to the organs or systems involved. 
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1. Gastro-intestinal complications 
- gastroparesis diabeticorum 
- constipation 
- oesophageal dysmotility 
- diarrhoea, and 
- faecal incontinence 
2. Metabolic disorders 
- hypoglycaemia unawareness 
- hypoglycaemia-associated autonomic failure 
3. Cardiovascular disorders 
- tachycardia 
- exercise intolerance 
- orthostatic hypotension 
4 .Genito-urinary disorders 
- neurogenic bladder 
- erectile dysfunction 
- female sexual dysfunction 
- retrograde ejaculation (Kolta et al., 1985). 
Cardiovascular autonomic neuropathy (CAN) 
Cardiovascular autonomic neuropathy is a complication of untreated diabetes mellitus 
that results from damage of neurones that innervate the blood vessels and the heart. This 
damage causes change in heart rate and blood flow. In diabetic patients with CAN, most 
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of the time, they manifest with orthostatic hypotension and exercise intolerance 
(Goodman and Gilman, 2001). 
Orthostatic hypotension 
This is a fall in blood pressure when the patient changes position from supine to standing. 
Orthostatic hypotension is a result of damage caused to an efferent nerve of the 
sympathetic nervous system. Normally, when an individual changes his/her position from 
supine to standing, there is an increase in noradrenaline release in order to maintain the 
blood pressure. In a patient with CAN, this response is not as efficient as it is seen in a 
normal individual. This failure causes a sudden drop in blood pressure, and a reduction 
in heart rate. An individual with orthostatic hypotension usually presents with 
lightheadedness, dizziness, fatigue and neck pain (Niakan et al., 1986) 
Exercise intolerance 
A patient with CAN may experience reduction in heart rate and fall in blood pressure 
during exercise. This condition may lead to reduced cardiac output and impaired oxygen 
perfusion as well as metabolic requirement of various organs in the body (Vinik et al., 
2003). 
Gastro-intestinal autonomic neuropathy 
Gastro-intestinal autonomic neuropathy complications are commonly present in patients 
with diabetes mellitus, and the severity of this condition is aggravated by other 
underlining conditions. Oesophageal dysfunction is associated with heart burn, delayed 
gastric emptying, anorexia, and nausea and vomiting. This disorder is caused by vagal 
neuropathy that leads to uncontrolled oesophageal peristaltism and impaired gastric 
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emptying. Because of the delay in bowel movements, there is overgrowth of bacteria that 
may contribute or initiate diarrhoea (Vinik et al., 2003). 
Genito-urinary autonomic neuropathy 
Diabetic autonomic neuropathy causes neurogenic bladder as a result of the damage 
caused on sensory and motor nerves. Deterioration of parasympathetic neurones may 
increase the supersensitivity of muscarinic receptors and increase bladder contraction. 
The damage of efferent nerve fibres to urinary bladder causes hesitancy, dribbling and 
weak/poor urine stream. The reduction in detrusor muscle activity causes increased post 
voiding residual urine, and subsequent urinary retention. The involvement of internal and 
external sphincter, owing to dennervation of these muscles, results in overflow 
incontinence. Urinary bladder dysfunction predisposes the patient to urinary tract 
infection and pyelonephritis, and may even lead to renal failure (Spigt et al, 2003; Spigt 
et al, 2004). 
Erectile dysfunction 
Erectile dysfunction (ED) is a consistent inability to have penile erection sufficient to 
sustain a satisfactory sexual intercourse. This condition must, at least, be present for 
several months to qualify as an erectile dysfunction. The cause of ED is multifactorial; it 
ranges from vascular disease, neuropathy, to metabolic disorder. Hyperglycaemia is 
responsible for glycation of fibres which impair the relaxation of corpora cavernosa, 
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causing failure of erectile mechanism. Many drugs have been used to reverse this 
situation, and these include sildenafil citrate (Viagra®). Erectile dysfunction may also be 
caused by dyslipidemia and endothelial dysfunction of sinusoidal cells, which decrease 
nitric oxide production, and thus reducing relaxation of penile muscles. In females, 
sexual dysfunction is characterized by a decreased sexual desire and dyspareunia during 
intercourse, due to inadequate vaginal lubrication (Vinik et al., 2003). 
Pathophysiology of urinary bladder in diabetic patient 
Diabetes mellitus is a syndrome that causes metabolic changes in the body and these 
changes are responsible for several complications that diabetic patients often experience. 
Usually, there is an increase in the amount of muscarinic receptors present in diabetic 
bladder. This condition leads to an increased contractility of detrusor muscles (receptor 
supersensitivity) (Kolta et al., 1985; Nakamura et al., 1992). More than 80% of diabetic 
patients suffer from urinary bladder dysfunction resulting from: 
(1) axonopathy of autonomic neurone of the urinary bladder, a myopathy caused by 
diuresis; and 
(2) alterations in adrenergic and muscarinic receptors caused by metabolic changes. 
Studies by Tong et al. (1999) on STZ-treated diabetic rats demonstrated the change in 
response of bladder detrusor muscle to different muscarinic agonists. This change was 
attributed to an increase in muscarinic receptors in the dome of urinary bladder of 
diabetic rats when compared with age-matched controls. The supersensitivity of M-
receptors is caused by deterioration of peripheral autonomic nerves, resulting from 
segmental demyelination and axonal degeneration. 
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Modulation of detrusor muscle hyperactivity 
Many factors are involved in the aetiology of urinary bladder hyperactivity. The central 
nervous system, neuronal extremity defect, and the pathology of urinary bladder muscle 
may be the major causes of urinary bladder hyperactivity. When sensory neurones are 
damaged, there is an increased frequency in micturition reflex, causing stimulation to 
occur at low volume of urine in the bladder. Fry et al. (2004) showed that stretch of the 
urothelium leads to release of adenosine triphosphate (ATP), which induces sensation of 
bladder fullness. For the control and stabilization of urothelium tissue sensitivity in the 
urinary bladder, detrusor muscle hyperactivity treatment must be of priority. 
Neurotransmitters such as acetylcholine, ATP, noradrenaline and their respective 
receptors are involved in the contraction of detrusor muscles. Normally, sensations of 
bladder fullness are propagated through pelvic and hypogastric nerve fibres; some of 
which are myelinated fiber-A8, while others are unmyelinated fibres-C. Investigations on 
these nerves, in normal individuals and in comparison with those of diabetic subjects, 
may reveal differences in their conductivity. Vanilloid receptors are involved in the 
sensory activity of urinary bladder to pH and temperature changes. Abnormal sensations 
may lead to hyperactivity or to relaxation of urinary bladder smooth muscle. Another 
tissue that has attracted attention of researchers is myofibroblast, because it plays a role 
in bladder fullness sensations. Myofibroblast is a layer interposed between nerve endings 
and urothelium, and it acts as an intermediary layer during the transmission of sensations. 
In diabetic patients, this layer may be impaired. This impairment leads to hypersensitivity 
of bladder fullness sensations, even with less urine in the bladder. In this tissue, there is a 
high density of non-neuronal P2X3 and VRi receptors on interstitial cells. These two 
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structures play a role in the sensation of bladder fullness. Microscopic observation of 
myofibroblasts revealed the following characteristics: fine cytoplasmic filaments linked 
to dense bodies, rough endoplasmic reticulum, vacuoles and Golgi apparatus. These 
structures are also innervated by neurones that release nitric oxide (NO) and GMP, 
mediators that are absent in detrusor muscle. This observation shows that there is another 
network of nerves that connect myofibroblasts that are not present in detrusor muscle. 
ATP and change in pH may stimulate the myofibroblast, and initiate micturition reflex 
(Liu and Daneshgari, 2005; Matsutomo et al., 2004). 
Drugs that affect urinary bladder 
Most of the drugs used in the treatment of urinary bladder dysfunction are chosen 
because of their mode of action, and are not specifically conceived for urinary bladder 
dysfunction. 
Anticholinergic agents 
Anticholinergic drugs are widely used in a variety of conditions that require treatment by 
inhibition of parasympathetic nervous system action. Some anticholinergic drugs are not 
selective for different sub-types of muscarinic M-receptors, and when used, they may 
cause more side-effects. Some anticholinergic compounds are natural, such as atropine 
and hyoscine found respectively in Atropa belladonna and Datura stramonium. Some of 
the anticholinergic drugs used in the treatment of urinary incontinence are tolterodine and 
oxybutynin, and they act by binding to muscarinic receptors. When ACh concentration 
increases at the receptor site, it displaces atropine which is a reversible antagonist. 
Because most anticholinergic agents are not specific on muscarnic receptors, their 
administration causes diverse side-effects (Kim et al., 2005). 
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Central Nerves System (CNS) 
Muscarinic M-receptor antagonists cause CNS depression that is characterized by 
amnesia, reduction of rapid eye movement sleep (REMS), drowsiness and euphoria. 
When atropine is used in a high dose, it causes hallucinations and delirium. 
Anticholinergic drugs are also used to treat side-effects resulting from the use of 
antipsychotic drugs such as haloperidol and chlorpromazine. 
Cardiovascular system 
Anticholinergic drugs increase heart rate (i.e., they cause tachycardia), and this is due to 
the inhibitory action of the drugs on vagal nerve through blockade of M2-receptors on the 
SA nodal pacemaker. 
Gastro-intestinal tract 
Anticholinergic drugs are used as antispasmodic agents, and in the treatment of gastric 
ulcers, owing to their inhibitory properties on vagal nerve. Salivary gland secretions are 
mediated through M3-receptors, and when selective M3-receptor blockers or non-
selective anticholinergics are used, the patient may experience dryness of mouth and 
reduction in gastric acid release. Anticholinergic drugs also reduce GIT motility and 
cause sphincter constriction, leading to constipation. 
Urinary bladder muscle 
Anticholinergic drugs reduce normal contraction (both tone and amplitude) of ureters and 
urinary bladder smooth muscles. To achieve these effects, the drugs must be able to 
inhibit muscarinic M2- and M3-receptors, and cause unwanted effects in other organs. 
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Respiratory tract 
Parasympathetic stimulation causes bronchoconstriction by the action of ACh on 
nicotinic and muscarinic receptors in post ganglionic fibers. This mode of action makes 
the drug to be useful in the treatment of asthma and chronic obstructive pulmonary 
disease. By inhibiting the secretions, anticholinergic agents help during procedures that 
involve the use of anaesthetic agents in order to prevent secretion and accumulation of 
fluid in the upper respiratory tract. 
Classification of muscarinic receptor antagonists 
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Selective muscarinic antagonists 
Triptamine and dariferacin are selective for muscarinic M2- and M3-receptors, and are 
used for the treatment of over-active bladder. 
Dariferacin 
Dariferacin has a higher affinity for muscarinic receptors. Its affinity for muscarinic Ms-
receptors is about 32-fold higher than for muscarinic M2-receptors. It is a muscarinic 
receptor antagonist with pseudo-irreversible activity. This drug is used for the treatment 
of bladder hyperactivity because it has an inhibitory effect on the contraction induced by 
non-muscarinic receptor agonists such as ATP. Dariferacin is metabolized by CYP2D6 
enzymes. 
Solifenacin 
Soliferacin has a 13-fold affinity for muscarinic M3-receptors than for muscarinic Ma-
receptors. It also binds to muscarinic Mi-receptors. This drug is used to treat 
incontinence, and it is able to reduce the number of urgency episodes and nocturia. The 
side-effects that accompany the use of solifenacin are: constipation and blurred vision. 
Trospium 
Trospium is an anticholinergic drug that has affinity for muscarinic Mi-, M2- and Ms-
receptors. It is a quaternary amine, and may also be used for the treatment of bladder 
incontinence. It has lower side-effects compared to solifenacin and darifenacin, but its 
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efficacy is quite the same as for those two drugs. It has a higher potency than oxybutynin 
in the treatment of bladder incontinence (Michel et ah, 2005). 
Tolterodine 
Tolterodine is an antimuscarinic drug that is commonly used in the treatment of 
incontinence. It acts on muscarinic M2- and M3-receptors. Even if it is not selective, it has 
less side-effect than oxybutynin, which acts only on M3, because it has a great affinity for 
urinary bladder smooth muscles (Michel et ah, 2005). 
Duloxetine 
Duloxetine is used in the treatment of diabetic peripheral neuropathy and stress urinary 
incontinence. It exerts its action by inhibiting re-uptake of serotonin and noradrenaline 
(Raskin et ai, 2006). 
Drugs affecting sympathetic pathways 
The urinary bladder is innervated by sympathetic nervous system from the rostral lumbar 
of spinal cord that release noradrenaline to the bladder dome and urethra. Noradrenaline 
has both excitatory and inhibitory input on the bladder and urethra. Before reaching the 
urinary bladder, sympathetic nerves from spinal cord release acetylcholine at the 
ganglionic level (pre-synaptic neurones), ACh thus released binds to nicotinic receptors 
and stimulate post-synaptic neurones that now noradrenaline to the urinary bladder and 
urethra. Noradrenaline contracts the bladder base and the urethral smooth muscle by its 
action on p- and ai-adrenergic receptors, respectively. Based on the above phenomenon, 
one may predict the effect of sympathomimetic and sympatholytic agents on urinary 
bladder and urethral internal sphincter (Goodman and Gilman, 2001). 
T 070207 
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Ganglionic blocking agents 
ACh is the neurotransmitter involved in stimulating the post-synaptic neurones owing to 
its action on nicotinic receptors. Agents like hexamethonium and trimethaphan block this 
pathway, thus preventing excitation of post-synaptic neurones which normally increase 
excitatory post-synaptic potential (EPSP). Inter-neurones store and release 
noradrenaline, some peptides and amino acids. EPSP is generated by the influx of Na+ 
and Ca2+ ions inside neurones through nicotinic receptor channels. The effects of 
ganglionic blocking agents depend on the division of autonomic nervous system that 
exerts a dominant control on a given organ. In the urinary bladder, this blockade causes 
atony of detrusor muscles. The non-selectivity of these agents often limits their clinical 
use and restricts their experimental usage. Some of the side-effects accompanying the 
use of ganglion blocking agents is cycloplegia, xerostomia, diminished perspiration, 
postural hypotension, and so on. Nevertheless, these agents are used in the management 
of autonomic hyper-reflexia, especially in patients with injuries to the upper spinal cord 
that causes excessive sympathetic discharge (Golan et al., 2005). 
Sympathomimetic agents 
The response of an organ to sympathomimetic agents depends on the presence of a- and 
P-adrenergic receptors on that particular organ. The extent of the effect is proportional to 
the density of these receptors and the affinity of these agents on different receptors. For 
example, agents that have a high affinity for P2-adrenergic receptors, have a greater effect 
on urinary bladder than those that have low affinity. The action of sympathomimetics on 
urinary bladder a-adrenergic receptors leads to the contraction of the trigone and internal 
sphincter of urethra. The use of these agents results in hesitancy in urination and in 
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urinary retention. Sympathomimetic agents have a limited use in the treatment of 
incontinence because of their severe side-effects on the heart and blood vessels. Agents 
such as minodrine, ephedrine and norephedrine act by direct stimulation of a- and p-
adrenoceptors, and can also induce the release of noradrenaline from sympathetic nerve 
terminals. The use of P-adrenoceptor antagonists is based on the fact that these agents 
reduce the effect of noradrenaline on a-adrenoceptors of urethral muscle. Imipramine, 
which inhibits reuptake of noradrenaline in nerve terminals, enhances the contractile 
effects of noradrenaline on urethra through a-adrenoceptors that exist on urethral smooth 
muscle (Golan et al., 2005). 
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CHAPTER FIVE 
BASIS OF THE PROJECT 
The mammalian urinary bladder is innervated and functionally regulated by the 
autonomic nervous system (ANS). Activation of the parasympathetic motor fibres to the 
bladder causes an intense stimulation of the muscarinic M3-receptors in the bladder body, 
resulting in a strong and efficient bladder contraction, which in turn causes emptying of 
the bladder. Urinary bladder dysfunction is a common complication of chronic diabetes 
mellitus. Vesical dysfunction is a well-known manifestation of the peripheral autonomic 
neuropathy that accompanies diabetes mellitus (Kamata et al, 1992). It has been 
suggested that the initial bladder distension seen in diabetic patients is a consequence of 
impaired sensory transmission, and sensory neuropathy has been shown to correlate with 
bladder neuropathy (Kamata et al., 1992; Hukovic et al., 1965). Contractile 
responsiveness of isolated bladder muscles from streptozotocin (STZ)-treated, diabetic 
rats to cholinergic nerve stimulation or administration of muscarinic agonist drugs has 
been studied by various investigators (Kamata et al, 1992; Carrier and Aronstam, 1990; 
Luheshi and Zar, 1991). Many studies have attempted to clarify the pathogenesis of the 
urinary bladder dysfunction seen in diabetes mellitus (Nakamura et al., 1992). It has been 
suggested that urinary bladder dysfunction in chronic diabetes might be due to an altered 
response of the organ to autonomic stimuli (Kamata et al., 1992). Segmental 
demyelination and axonal degeneration of the peripheral autonomic nerves have also 
been reported to cause dysfunction of lower urinary bladder tract (Van Poppel et al., 
1988). Several studies have been undertaken to investigate contractile responses of the 
bladder to muscarinic drugs in diabetic animals. It has been shown that in diabetic 
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animals, contractile responses of the urinary bladder to muscarinic agonists are 
inconsistent. Some investigators have reported increased responses (Kamata et al., 1992; 
Kolta et al., 1985; Latifpour et al., 1988 ; Tong and Cheng, 2002), while others have 
reported decreased responses (Longhurst and Belis, 1986 ; Lunghurst et al., 1990) or no 
change in contractile responses (Luheshi and Zar, 1991 ; Lincoln et al., 1984) of diabetic 
urinary bladder smooth muscle strips to muscaric agonists. The present study was, 
therefore, prompted by the existing controversies and inconsistencies in the biomedical 
literature on the responses of diabetic urinary bladders to muscarinic agonists. 
STUDY OBJECTIVE 
The core aim of this study was, therefore, to investigate the responses of urinary bladders 
isolated from normal (normoglycaemic) and STZ-treated, diabetic Wistar rats to 
acetylcholine (ACh), a prototype muscarinic agonist. 
EXPERIMENTAL PROTOCOL AND PROCEDURES 
MATERIALS AND METHODS 
The experimental protocol and procedures used in this study were approved by the Ethics 
Committee of the University of KwaZulu-Natal, Durban 4000, South Africa; and 
conform with the "Guide to the Care and Use of Animals in Research and Teaching" 
[published by the Ethics Committee of the University of Durban-Westville, Durban 4000, 
South Africa]. 
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Animals and induction of diabetes 
Thirty (30) healthy, young adult, male Wistar rats {Rattus norvegicus) weighing 250-300 
g, were used. The animals were kept and maintained under laboratory conditions of 
temperature, humidity, and light; and were allowed free access to food and water ad 
libitum one week before the commencement of my experiments. The rats were divided 
into two groups of fifteen age-matched, normal (non-diabetic) and fifteen STZ-treated, 
diabetic animals; and were kept in separate cages. Diabetes was induced in the diabetic 
group of rats by intraperitoneal injections of STZ (75 mg/kg). The STZ-treated rats were 
kept in their cages for 7-10 days under laboratory conditions, to allow diabetes to 
develop in the animals. Two-to-ten-week diabetic rats were used in this study. 
Preparation of Bladder Tissues 
STZ-treated rats with blood glucose concentrations >18 mmol/L were considered to be 
diabetic and used in this study. The normal (non-diabetic) and STZ-treated diabetic rats 
were sacrificed by decapitation, and the whole (entire) Urinary bladder of each rat was 
removed, opened up longitudinally to form a semi-rectangular piece of tissue, tied with 
cotton thread at the upper and lower ends, and suspended in 30-ml 'Ugo Basile Two-
Chambered Organ Baths' (model 4050) containing Krebs-Henseleit physiological 
solution (of composition, in g/litre: NaCl, 6.29; KC1, 0.34; NaH2PO4,0.15; NaHC03, 2.1; 
MgCl2, 0.11; CaCb, 0.26; and glucose, 1.00) maintained at 32±1°C and continuously 
aerated with carbogen (i.e., 5% carbon-dioxide + 95% oxygen gas mixture) under an 
applied resting tension of 1 g. Each bladder muscle strip was allowed to equilibrate for 
45-60 minutes, during which time the bathing physiological solution was changed every 
55 
15 minutes, before it was challenged with graded concentrations of ACh (and other drugs 
used). 
Acetylcholine (ACh) Treatment 
Each isolated urinary bladder muscle strip was challenged with graded concentrations of 
acetylcholine (ACh, 10"8-10"4 M) in the absence, and in the presence, of atropine (ATR, 
10"7-10"5 M). The tissues were washed out 3-5 times after the maximal contractile 
response to each ACh concentration was obtained, and thereafter allowed to equilibrate 
for 5-10 minutes before sequential addition of the next higher concentration of 
acetylcholine. Isolated urinary bladder strips from diabetic and normal, age-matched 
control animals were always set-up in parallel under the same experimental conditions, in 
order to make allowance for adequate comparison of the tissues' contractile responses to 
acetylcholine. The ACh-induced contractile responses of the tissues were recorded 
isometrically by means of 'Ugo Basile' force displacement transducers and pen-writing 
'Gemini' recorders (model 7070). 
Data Analysis 
Data obtained are presented as means (±SEM) of the contractile responses of the bladder 
tissues to the various ACh concentrations. Statistical evaluation of the data was done by 




Changes in blood glucose concentrations, body and bladder weights 
One to ten weeks after treatment with STZ, the fasting blood glucose concentrations of 
the STZ-treated, diabetic rats were significantly elevated (P<0.05-0.001), compared with 
those of the normal (non-diabetic), age-matched, control rats (Table 1). Furthermore, the 
body weights of the STZ-treated, diabetic rats decreased significantly (P<0.05-0.01) after 
six weeks of STZ treatment, compared with the normal (non-diabetic), age-matched, 
control rats. The bladders of the STZ-treated, diabetic rats were visibly more distended 
and larger than those of the normal, age-matched control rats at the time of dissection. 
Moreover, the wet weights of the bladders from diabetic rats were significantly greater 
(P<0.05-0.01) than those from normal (non-diabetic), age-matched control rats (Table 1). 
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Figure 1. 
Effects of graded concentrations of acetylcholine (ACh) on isolated urinary bladder 
muscle strips from a normal rat bladder (NRB, upper trace) and a diabetic rat bladder 
(DRB, lower trace) respectively. ACh A 1, 2, 3, 4 and 5 denote acetylcholine, 5.0 x 10"8, 
5.0 x 10"7, 5.0 x 10"6, 5.0 x 10"5 and 5.0 x 10"4 M respectively, sequentially added to the 
bath-fluid at the solid dots (A), and washed out 3-5 times at the adjacent, open right-
hand-side, downward-pointing arrows. 
58 
^ 1 0 0 - . •- Diabetic bladder (DRB) 
-±— Normal bladder (NRB) 
-7 -6 -5 -4 
Log ACh Concentration [M] 
Figure 2. 
Comparative effects of graded concentrations of acetylcholine (ACh) on tension developed by isolated urinary bladder tissues from 
normal (A, NRB) and diabetic (•, DRB) rats. Each point represents the mean of 15 preparations, while the vertical bars denote 
standard errors of the means. 
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Table 1. 
Fasting blood glucose (FBG) levels, body weights and wet weights of isolated bladders of normal 
(non-diabetic) and STZ-treated, diabetic rats at week 10 of the study period. 
Parameter 
Fasting blood glucose 
(FBG) levels (in mmol/L) 
Body weights (g) 
Bladder wet weights (g) 











Acetylcholine-induced contractile responses of the isolated bladders 
Acetylcholine (ACh, 10"8-10"4 M) caused concentration-dependent contractions of 
bladders isolated from both non-diabetic and STZ-treated, diabetic rats. However, 
acetylcholine always induced stronger, more powerful and greater contractions of the 
diabetic bladders compared with bladders from the non-diabetic, age-matched control 
rats. Figure 1 illustrates typical traces obtained, while Figure 2 summarises the results 
obtained. The enhanced contractile responses of the diabetic bladder strips to bath-
applied ACh were detected soon after induction of diabetes, and the magnitude or 
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intensity of the enhanced contractile responses to ACh continued to increase steadily and 
linearly as the diabetic state of the animals progressed from one week to ten weeks. 
Atropine (ATR, 10"7-10"5 M), a muscarinic antagonist, inhibited the contractile responses 
of the isolated bladder preparations to bath-applied acetylcholine in a concentration-
dependent manner. The mean EC50 values for ACh on the isolated whole bladders of 
diabetic and age-matched, non-diabetic control rats were found to be 0.01±0.08 x 10"6 M 
(n=15) and 7.21±0.10 x 10"5 M (n=15), respectively. 
DISCUSSION 
The results of the present study show that acetylcnoline (ACh) induced stronger, more 
powerful and much greater contractions of isolated bladders from STZ-treated, diabetic 
rats compared with bladders isolated from normal (non-diabetic), age-matched, control 
rats. It is now firmly established that the sympathetic and parasympathetic nervous 
systems of the autonomic nervous system (ANS) regulate the functions of the lower 
urinary bladder in different ways. During the storage phase, the roles of the sympathetic 
nervous system are relaxation of the bladder body, and contraction of the bladder base 
through a- and P-adrenoceptors, respectively; whereas, the role of the parasympathetic 
nervous system is a contraction of the detrusor muscle through stimulation of the 
muscarinic M3-receptors in the bladder body to expel urine (Nakamura et al, 1992; 
Frimondt, 1976). Lincoln et al. (1984) showed significant increases in the activities of 
choline acetyltransferase and choline esterase in the rat bladder after two to eight weeks 
of diabetes, suggesting that cholinergic nerve activity is increased in the urinary bladder 
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during diabetes. The investigators (Lincoln et al., 1984) further observed that 
norepinephrine content in the bladder showed a tendency to decrease in diabetes. 
Previous investigators have shown that in diabetic animals, the contractile response of the 
urinary bladder to muscarinic agonists is inconsistent. Some investigators have reported 
increased contractile responses (Kamata et al., 1992; Kolta et al., 1985; Latifpour et al, 
1988), while others have reported either decreased responses (Longhurst and Belis, 1986) 
or no change in contractile responses (Luheshi and Zar, 1991; Nakamura et al., 1992; 
Lincoln et al., 1984) of the urinary bladder smooth muscle to muscarinic agonists. 
Latifpour et al. (1988) and Tong and Cheng (2002) have also reported an increased 
number of muscarinic M3-receptors associated with increased contractile responses to 
muscarinic agonists in the bladder dome of STZ-treated diabetic rats. On the contrary, 
Carrier and Aronstam (1990) have reported an increased muscarinic responsiveness and a 
decreased density of muscarinic receptors in ileal smooth muscles from STZ-treated, 
diabetic rats. Kamata et al. (1992) have also shown that detrusor strips of urinary 
bladders from STZ-treated diabetic rats exhibit an enhanced contractile response to 
acetylcholine, and associated the increased responses to ACh with an increased 
population of muscarinic receptors in the tissues. However, findings of this study are in 
agreement with the observations of Kolta et al. (1985); Latifpour et al. (1988); and 
Kamata et al. (1992) who have reported increased contractile responses of diabetic 
bladders to muscarinic agonists. The discrepancies in the findings of the various earlier 
investigators who have examined contractile responses of isolated urinary bladders from 
diabetic mammals to acetylcholine (or parasympathetic nerve stimulation) are unlikely to 
be due to differences in species, strains and ages of the experimental animals used 
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because my preliminary studies also showed enhanced, increased contractile responses of 
isolated bladders from all available diabetic species and strains of mice, rats, guinea-pigs 
and rabbits of different ages to bath-applied acetylcholine. However, the duration of 
hyperglycaemia, the segment of the bladder used the breeders of the animals and the 
experimental conditions employed, might contribute significantly to the differences in the 
findings of the earlier investigators. Nilvebrant et al. (1986) and Tong and Cheng (2002) 
noted "supersensitivity" to muscarinic agonists, and an increased density of muscarinic 
M3-receptors. Nilvebrant et al. (1986) also noted no change in affinity for 3H-QNB with 
hypertrophied bladders following peripheral parasympathetic denervation of the urinary 
bladders. Latifpour et al. (1988) have also shown that STZ-induced diabetic state causes 
an increased maximum contractile response to muscarinic agonist, an increased density of 
muscarinic receptors, and no change in the affinity of the bladder dome smooth muscle 
for 3H-QNB. However, in their study, Kamata et al. (1992) found that muscarinic 
receptors in the detrusor strips from STZ-treated diabetic rats had a lower affinity for 3H-
QNB than the detrusor strips from normal, control rats. The latter investigators (Kamata 
et al, 1992) concluded that although it is unclear why the affinity for 3H-QNB was lower 
in diabetic state, it is unlikely that the decreased affinity of muscarinic receptors to 
acetylcholine is related to the increased contractile response to acetylcholine (ACh). 
The findings of the present study are in agreement with the works of Kolta et al. (1985) 
and Tammela et al. (1995) who observed enhanced and significantly greater responses of 
bladder strips from diabetic rats to acetylcholine and carbachol respectively, soon after 
induction of diabetes with STZ. The investigators (Kolta et al., 1985; Tammela et al, 
1995) further observed that the magnitude and/or intensity of the acetylcholine- and 
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carbachol-induced contractile responses of the diabetic bladder strips continued to 
increase as the diabetic state of the animals progressed. The increased diabetic bladder 
mass observed in the present study is also in consonance with the findings of Tammela et 
al. (1995) who found a significantly increased diabetic bladder mass in their study, and 
concluded that effects of diabetes (and sucrose consumption) on contractile bladder 
function are related to diuresis-induced increases in bladder mass. 
In conclusion, the findings of the present study have demonstrated that urinary bladders 
from STZ-treated diabetic rats exhibit an increased contractile responsiveness to bath-
applied acetylcholine. Although the present study could not establish the mechanism of 
the increased contractile responsiveness of the diabetic bladders to the muscarinic agonist 
(ACh) used, my findings tend to suggest that the alterations in diabetic urinary bladder 
synaptosomal, vesicle-bound neurotransmitter (ACh) concentrations reported by Tong et 
al. (1996), and the compensatory increase in the density of muscarinic M3-receptor 
population reported by Latifpour et al. (1988) would appear to be two of the most 
plausible mechanisms of the increased diabetic bladder responsiveness to acetylcholine. 
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CHAPTER SIX 
Study Constraints and Recommendations for Future Studies 
This study, like many other experimental studies, encountered a number of obstacles and 
constraints, without which its outcome would probably have been much better. The 
restriction on the number of experimental animals allowed in this study meant that only a 
limited number of rats (30) could be used for the study. This restriction may pose a threat 
to statistical analysis of results. In this study, only one animal species (rat) was used. It 
would have been better to use other animal species (e. g., guinea-pigs, rabbits, etc) as 
well for meaningful comparison. Because of time and financial constraints, I was unable 
to carry out receptor studies and cloning experiments, which would have shed more light 
on the mechanism of action of ACh in diabetic rat bladders, and improve the quality of 
the present experimental findings generally - probably by identifying the muscarinic 
receptor subtypes and population/s in diabetic rat bladders. The sensitivity and accuracy 
of the recording equipment used can only be assumed for the measurement of the small 
differences that existed between the two experimental animal groups. 
Recommendations for future studies 
1. It would be interesting to extend this study to other animal species (especially, 
mice, guinea-pigs and rabbits) to see if 'species variation' affects the 
responsiveness of diabetic bladders to ACh. 
2. Receptor studies should be undertaken to throw more light on the mechanism of 
the enhanced responsiveness of diabetic bladders to ACh. The mechanistic studies 
should include determination of muscarinic receptor subtype population and/or 
density in the bladders of diabetic and non-diabetic animals. 
3. The effects of other neurotransmitters, especially noradrenaline and adenosine 
triphosphate (ATP), on diabetic and non-diabetic bladders should also be 
investigated in great detail. 
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